Skip to main content
. Author manuscript; available in PMC: 2017 Mar 3.
Published in final edited form as: Eur J Med Chem. 2016 Jan 21;110:164–180. doi: 10.1016/j.ejmech.2016.01.017

Table 3.

Anti-Proliferative Activity of Selected 1,7-diheteroarylhepta-1,4,6-trien-2-ones

Compd IC50 (μM)a IC50 (curcumin) / IC50 (compd)
PC-3b DU145c LNCaPd HeLae PC-3b DU145c LNCaPd HeLae
Curcumin 25.43 ± 2.15 26.23 ± 0.65 13.61 ± 2.69 12.11 ± 0.67 1 1 1 1
13 2.56 ± 0.14 1.62 ± 0.57 1.56 ± 0.12 0.98 ± 0.18 10 16 9 12
14 2.54 ± 0.10 1.82 ± 0.43 1.79 ± 0.63 1.04 ± 0.07 10 14 8 12
15 1.88 ± 0.32 1.07 ± 0.28 1.21 ± 0.21 0.82 ± 0.08 14 25 11 15
17 1.59 ± 0.37 0.94 ± 0.05 1.32 ± 0.14 0.75 ± 0.08 16 28 10 16
18 1.55 ± 0.04 0.91 ± 0.26 1.03 ± 0.11 0.71 ± 0.04 16 29 13 17
30 0.70 ± 0.08 0.91 ± 0.04 1.29 ± 0.51 0.36 ± 0.11 36 29 11 34
31 2.31 ± 0.35 1.61 ± 0.20 2.82 ± 0.09 1.35 ± 0.38 11 16 5 9
32 1.03 ± 0.07 1.01 ± 0.27 1.23 ± 0.52 0.82 ± 0.11 25 26 11 15
33 1.62 ± 0.11 1.85 ± 0.25 2.83 ± 0.80 1.11 ± 0.21 16 14 5 11
35 1.06 ± 0.08 1.09 ± 0.37 2.00 ± 0.45 1.02 ± 0.12 24 24 7 12
a

IC50 is the drug concentration effective in inhibiting 50% of the cell viability measured by WST-1 cell proliferation assay (WST-1) after 3 days exposure.

b

Human androgen-insensitive prostate cancer cell line

c

Human androgen-insensitive prostate cancer cell line

d

Human androgen-sensitive prostate cancer cell line

e

Human aggressive cervical cancer cell line